| Literature DB >> 34605855 |
Dana Marafi1,2, Jawid M Fatih1, Rauan Kaiyrzhanov3, Matteo P Ferla4,5, Charul Gijavanekar1,6, Aljazi Al-Maraghi7, Ning Liu1,6, Emily Sites8, Hessa S Alsaif9, Mohammad Al-Owain10,11, Mohamed Zakkariah12, Ehab El-Anany12, Ulviyya Guliyeva13, Sughra Guliyeva13, Colette Gaba14, Ateeq Haseeb15, Amal M Alhashem16, Enam Danish17, Vasiliki Karageorgou18, Christian Beetz18, Alaa A Subhi19, Sureni V Mullegama20, Erin Torti20, Monisha Sebastin21,22, Margo Sheck Breilyn21,23, Susan Duberstein24, Mohamed S Abdel-Hamid25, Tadahiro Mitani1, Haowei Du1, Jill A Rosenfeld1,6, Shalini N Jhangiani26, Zeynep Coban Akdemir1,27, Richard A Gibbs1,26, Jenny C Taylor4,5, Khalid A Fakhro7,28,29, Jill V Hunter30,31, Davut Pehlivan1,32,33, Maha S Zaki34, Joseph G Gleeson35, Reza Maroofian3, Henry Houlden3, Jennifer E Posey1, V Reid Sutton1,6,32, Fowzan S Alkuraya9, Sarah H Elsea1,6, James R Lupski1,26,32,36.
Abstract
The solute carrier (SLC) superfamily encompasses >400 transmembrane transporters involved in the exchange of amino acids, nutrients, ions, metals, neurotransmitters and metabolites across biological membranes. SLCs are highly expressed in the mammalian brain; defects in nearly 100 unique SLC-encoding genes (OMIM: https://www.omim.org) are associated with rare Mendelian disorders including developmental and epileptic encephalopathy and severe neurodevelopmental disorders. Exome sequencing and family-based rare variant analyses on a cohort with neurodevelopmental disorders identified two siblings with developmental and epileptic encephalopathy and a shared deleterious homozygous splicing variant in SLC38A3. The gene encodes SNAT3, a sodium-coupled neutral amino acid transporter and a principal transporter of the amino acids asparagine, histidine, and glutamine, the latter being the precursor for the neurotransmitters GABA and glutamate. Additional subjects with a similar developmental and epileptic encephalopathy phenotype and biallelic predicted-damaging SLC38A3 variants were ascertained through GeneMatcher and collaborations with research and clinical molecular diagnostic laboratories. Untargeted metabolomic analysis was performed to identify novel metabolic biomarkers. Ten individuals from seven unrelated families from six different countries with deleterious biallelic variants in SLC38A3 were identified. Global developmental delay, intellectual disability, hypotonia, and absent speech were common features while microcephaly, epilepsy, and visual impairment were present in the majority. Epilepsy was drug-resistant in half. Metabolomic analysis revealed perturbations of glutamate, histidine, and nitrogen metabolism in plasma, urine, and CSF of selected subjects, potentially representing biomarkers of disease. Our data support the contention that SLC38A3 is a novel disease gene for developmental and epileptic encephalopathy and illuminate the likely pathophysiology of the disease as perturbations in glutamine homeostasis.Entities:
Keywords: SLC38A3; biallelic; glutamate transporter; glutamate/GABA-glutamine cycle
Mesh:
Substances:
Year: 2022 PMID: 34605855 PMCID: PMC9050560 DOI: 10.1093/brain/awab369
Source DB: PubMed Journal: Brain ISSN: 0006-8950 Impact factor: 15.255